3-phenylcoumarins bearing aminoalkoxy moiety has been designed to treat Alzheimer’s disease by inhibiting acetylcholinesterase and butyrylcholinesterase [51]. Here, ACHE is linked to early-onset autosomal dominant Alzheimer disease.